Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity

Neutralizing antibodies (nAbs) are pivotal in developing fast, broadly protective therapeutics against novel pandemic viruses. Despite their well-known direct neutralization capacity, their effector mechanisms via Fc receptors remain poorly understood. Identifying the types of effector cells engaged in antibody-mediated effector functions is essential for regulating their activities. Using the lymphocytic choriomeningitis virus (LCMV), we show that nAbs obtained from immune sera or monoclonal LCMV-specific nAbs show dependency on Fc receptors. We demonstrate that therapy with nAbs is highly protective in the presence of patrolling monocytes. These monocytes bind nAbs primarily via FcγRIV, targeting virus-infected cells, and thereby limiting virus propagation. Depleting patrolling monocytes or blocking FcγRIV resulted in a substantial loss of virus control by nAbs, indicating the pivotal role of patrolling monocytes in the antiviral activity of these antibodies. In conclusion, our findings highlight that, alongside direct neutralization, nAbs primarily exert their effects through the involvement of patrolling monocytes.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-05-29
DOI
https://doi.org/10.3389/fimmu.2025.1600056
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity

Karl S. Lang, Harpreet Kaur, Wiebke Hansen, Hossam Abdelrahman et al.
Frontiers in Immunology
SARS-CoV-2 and COVID-19 Research
article

Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity

Karl S. Lang, Harpreet Kaur, Wiebke Hansen, Hossam Abdelrahman, Judith Lang, Julia Falkenstein, Matthias Mack, Falk Nimmerjahn, Abdelrahman Elwy, Lisa Holnsteiner, Theresa Charlotte Christ, Julia Specht, Swati Dhiman
article en

Abstract

Neutralizing antibodies (nAbs) are pivotal in developing fast, broadly protective therapeutics against novel pandemic viruses. Despite their well-known direct neutralization capacity, their effector mechanisms via Fc receptors remain poorly understood. Identifying the types of effector cells engaged in antibody-mediated effector functions is essential for regulating their activities. Using the lymphocytic choriomeningitis virus (LCMV), we show that nAbs obtained from immune sera or monoclonal LCMV-specific nAbs show dependency on Fc receptors. We demonstrate that therapy with nAbs is highly protective in the presence of patrolling monocytes. These monocytes bind nAbs primarily via FcγRIV, targeting virus-infected cells, and thereby limiting virus propagation. Depleting patrolling monocytes or blocking FcγRIV resulted in a substantial loss of virus control by nAbs, indicating the pivotal role of patrolling monocytes in the antiviral activity of these antibodies. In conclusion, our findings highlight that, alongside direct neutralization, nAbs primarily exert their effects through the involvement of patrolling monocytes.

Frontiers in ImmunologyVol. 16
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University Hospital Regensburg (DE), University of Duisburg-Essen (DE)
Universität Duisburg-Essen
Good health and well-being
Openalex Percentile: Top 84%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.